BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 34604061)

  • 1. Axitinib and HDAC Inhibitors Interact to Kill Sarcoma Cells.
    Roberts JL; Booth L; Poklepovic A; Dent P
    Front Oncol; 2021; 11():723966. PubMed ID: 34604061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GZ17-6.02 and axitinib interact to kill renal carcinoma cells.
    Booth L; West C; Moore RP; Hoff DV; Dent P
    Oncotarget; 2022; 13():281-290. PubMed ID: 35136485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The multi-kinase inhibitor lenvatinib interacts with the HDAC inhibitor entinostat to kill liver cancer cells.
    Roberts JL; Poklepovic A; Booth L; Dent P
    Cell Signal; 2020 Jun; 70():109573. PubMed ID: 32087304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. (Curcumin+sildenafil) enhances the efficacy of 5FU and anti-PD1 therapies in vivo.
    Dent P; Booth L; Roberts JL; Poklepovic A; Hancock JF
    J Cell Physiol; 2020 Oct; 235(10):6862-6874. PubMed ID: 31985048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GZ17-6.02 initiates DNA damage causing autophagosome-dependent HDAC degradation resulting in enhanced anti-PD1 checkpoint inhibitory antibody efficacy.
    Booth L; Roberts JL; West C; Von Hoff D; Dent P
    J Cell Physiol; 2020 Nov; 235(11):8098-8113. PubMed ID: 31951027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GZ17-6.02 Interacts With [MEK1/2 and B-RAF Inhibitors] to Kill Melanoma Cells.
    Booth L; West C; Von Hoff D; Kirkwood JM; Dent P
    Front Oncol; 2021; 11():656453. PubMed ID: 33898322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neratinib and entinostat combine to rapidly reduce the expression of K-RAS, N-RAS, Gα
    Booth L; Roberts JL; Sander C; Lalani AS; Kirkwood JM; Hancock JF; Poklepovic A; Dent P
    Cancer Biol Ther; 2019; 20(5):700-710. PubMed ID: 30571927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Lethality of [Pazopanib + HDAC Inhibitors] Is Enhanced by Neratinib.
    Booth L; Roberts JL; Poklepovic A; Dent P
    Front Oncol; 2019; 9():650. PubMed ID: 31380285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The CHK1 inhibitor SRA737 synergizes with PARP1 inhibitors to kill carcinoma cells.
    Booth L; Roberts J; Poklepovic A; Dent P
    Cancer Biol Ther; 2018; 19(9):786-796. PubMed ID: 30024813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo.
    Booth L; Roberts JL; Sander C; Lee J; Kirkwood JM; Poklepovic A; Dent P
    Oncotarget; 2017 Mar; 8(10):16367-16386. PubMed ID: 28146421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GZ17-6.02 and Pemetrexed Interact to Kill Osimertinib-Resistant NSCLC Cells That Express Mutant ERBB1 Proteins.
    Booth L; West C; Moore RP; Von Hoff D; Dent P
    Front Oncol; 2021; 11():711043. PubMed ID: 34490108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GZ17-6.02 and Doxorubicin Interact to Kill Sarcoma Cells via Autophagy and Death Receptor Signaling.
    Booth L; West C; Hoff DV; Dent P
    Front Oncol; 2020; 10():1331. PubMed ID: 32983965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody
    Booth L; Roberts JL; Poklepovic A; Avogadri-Connors F; Cutler RE; Lalani AS; Dent P
    Oncotarget; 2017 Oct; 8(52):90262-90277. PubMed ID: 29163826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Valproate augments Niraparib killing of tumor cells.
    Booth L; Roberts JL; Rais R; Poklepovic A; Dent P
    Cancer Biol Ther; 2018; 19(9):797-808. PubMed ID: 29923797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GZ17-6.02 and palbociclib interact to kill ER+ breast cancer cells.
    Booth L; West C; Moore RP; Von Hoff D; Dent P
    Oncotarget; 2022; 13():92-104. PubMed ID: 35035775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The irreversible ERBB1/2/4 inhibitor neratinib interacts with the BCL-2 inhibitor venetoclax to kill mammary cancer cells.
    Booth L; Roberts JL; Avogadri-Connors F; Cutler RE; Lalani AS; Poklepovic A; Dent P
    Cancer Biol Ther; 2018 Mar; 19(3):239-247. PubMed ID: 29333953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HDAC inhibitors enhance the immunotherapy response of melanoma cells.
    Booth L; Roberts JL; Poklepovic A; Kirkwood J; Dent P
    Oncotarget; 2017 Oct; 8(47):83155-83170. PubMed ID: 29137331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pazopanib and HDAC inhibitors interact to kill sarcoma cells.
    Tavallai S; Hamed HA; Grant S; Poklepovic A; Dent P
    Cancer Biol Ther; 2014 May; 15(5):578-85. PubMed ID: 24556916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NEDD4 over-expression regulates the afatinib resistant phenotype of NSCLC cells.
    Booth L; Roberts JL; Poklepovic A; Dent P
    Oncol Signal; 2018 Jun; 1(1):19-30. PubMed ID: 30740589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TGF-β-activated kinase 1 (TAK1) mediates cadmium-induced autophagy in osteoblasts via the AMPK / mTORC1 / ULK1 pathway.
    Ran D; Ma Y; Liu W; Luo T; Zheng J; Wang D; Song R; Zhao H; Zou H; Gu J; Yuan Y; Bian J; Liu Z
    Toxicology; 2020 Sep; 442():152538. PubMed ID: 32693121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.